Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it
will be showcasing its latest product innovations at the Society of
Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake
City. Complementing an already extensive product line, the new
innovations provide exciting new opportunities for advancing
preclinical and organoid-focused therapy development.
DSI™ Ponemah™ Data Management Platform Provides
Integrated Preclinical Solution
The Company’s industry-leading GLP-compliant Ponemah™
preclinical data management platform now includes integrations with
the new SoHo™ implantable telemetry solution and the VivaMARS™
high-capacity behavior monitoring system.
By integrating these new applications in a single data
management platform, the Ponemah system provides users with a
powerful tool for managing and analyzing data across a range of
studies. The integrated platform also opens new opportunities for
the use of emerging machine learning-based algorithms to
efficiently analyze large data pools.
SoHo™ Implantable Real-Time Telemetry for Small Animal
Models
Together with the Ponemah platform, the SoHo telemetry solution
enables researchers to collect, manage, analyze and report findings
from multiple concurrent small animal models in a more natural
shared housing environment. In addition, the SoHo solution allows
data to be collected over longer time periods and opens exciting
new opportunities for longitudinal studies. SoHo supports the
customer’s business needs by reducing operating costs and test
cycle times, enabling increased testing throughput. For more
information visit the DSI website at
https://www.datasci.com/products/implantable-telemetry/soho-telemetry-system.
VivaMARS™ Activity Monitoring System
The VivaMARS system combines the Company’s infrared Panlab®
activity monitoring technology with its Ponemah platform to create
an integrated, GLP-compliant solution for real-time, high precision
behavioral testing. The system is ideally suited to meet the high
throughput, automated neuropharmacology and neurotoxicology testing
needs of CROs and pharma companies, in addition to longitudinal
behavior studies carried out by leading research and academic
institutes. For more information on the VivaMARS system, visit the
DSI website
at https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system.
MCS™ Mesh MEA™ Organoid Platform
The Company will also exhibit its new organoid-centric mesh
Microelectrode Array (MEA) platform. Expanding on its recognized
leadership position in in-vitro MEA products, the new
Mesh MEA™ platform allows researchers to capture precise
electrophysiology measurements from inside the living organoid in
real time. The new Mesh MEA platform is designed for the emerging
applications of organoids in research and discovery, safety
pharmacology and toxicology. For more information on our mesh MEA
products and organoid research, visit our website
at https://www.harvardbioscience.com/applications/organoid-research.
Solutions for New Therapy Development
Jim Green, Harvard Bioscience Chairman and CEO, said, “We are
pleased to offer our CRO, pharma, and biotech customers innovative
products designed to reduce cycle times, improve throughput, and
reduce time to market. Looking to the future, I’m especially
excited by the potential of our Ponemah platform to advance the use
of emerging artificial intelligence (AI) and machine learning
technologies to streamline data analysis and reporting in
applications such as toxicology and organoid testing.”
Serge Savard, Harvard Bioscience Vice President of Product
Management, said, “By integrating these new applications in a
single data management platform, our Ponemah system provides a
proven solution for preclinical testing. And, with the emergence of
new machine learning technologies and their potential to automate
the analysis and review of large data sets, we are already starting
to receive customer interest in extending the Ponemah platform to
incorporate these technologies.”
Booth at Society of Toxicology
The Company will be exhibiting a range of solutions at Society
of Toxicology booth #2304, at the Salt Palace Convention Center
(Salt Lake City, UT). Representatives will be present during
exhibit hours from Monday, March 11, 2024 through Wednesday, March
13, 2024.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer
and seller of technologies, products and services that enable
fundamental advances in life science applications, including
research, pharmaceutical and therapy discovery, bio-production and
preclinical testing for pharmaceutical and therapy development. Our
customers range from renowned academic institutions and government
laboratories to the world’s leading pharmaceutical, biotechnology
and contract research organizations. With operations in North
America, Europe, and China, we sell through a combination of direct
and distribution channels to customers around the world.
For more information, please visit our website
at https://www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the
meaning of the federal securities laws, including the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “may,”
“will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and
similar expressions or statements that do not relate to historical
matters. Forward-looking statements include, but are not limited
to, information concerning expected future financial and
operational performance including revenues, gross margins,
earnings, cash and debt position, growth and the introduction of
new products, and the strength of the Harvard Bioscience, Inc. (the
“Company”) market position and business model. Forward-looking
statements are not guarantees of future performance and involve
known and unknown uncertainties, risks, assumptions, and
contingencies, many of which are outside the Company’s control.
Risks and other factors that could cause the Company’s actual
results to differ materially from those described its
forward-looking statements include those described in the “Risk
Factors” section of the Company’s most recently filed Annual Report
on Form 10-K as well as in the Company’s other filings with the
Securities and Exchange Commission. Forward-looking statements are
based on the Company’s expectations and assumptions as of the date
of this document. Except as required by law, the Company assumes no
obligation to update forward-looking statements to reflect any
change in expectations, even as new information becomes
available.
Inquiries:
CustomersSales@datasci.com
Investors and MediaHarvard Bioscience, Inc.Investor
Relationsinvestors@harvardbioscience.com(508) 893-3120
Harvard Bioscience (NASDAQ:HBIO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Harvard Bioscience (NASDAQ:HBIO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024